- Home
- Companies
- Eligo Bioscience
- Products
- Eligobiotics - Microbiome Technology
Eligobiotics - Microbiome Technology
Eligobiotics are a first-in-class proprietary modality that enables the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology allows modulation of the microbiome’s composition and function to address human disease with an unprecedented precision.
Sequence-Specific Anti-Microbials
Therapeutic payload: exogenous CRISPR-Cas nuclease gene and its corresponding guide RNA
MoA: Once the DNA payload is injected in the bacteria, the nuclease is expressed and its corresponding guide RNA will guide it toward bacterial genomic sequences homologous to the guide RNA. If such sequences are present, the nuclease will create targeted DNA double-strand breaks, leading to the death of the bacteria. If these sequences are absent from the bacteria, the nuclease won’t create any double-strand breaks, and the bacteria will be left intact.
Function Addition to the MicrobiomE
Therapeutic payload: single gene cassette/operon or multiple gene cassettes/operon(s) – up to 50kb
MoA: Once the non-replicative DNA payload is injected in the bacteria, the gene(s) will be efficiently expressed to have the desired effect on the host.